Sendai Virus Vector

1. Front Matter

   Pages i-xii

   PDF

2. Reverse Genetics of Mononegavirales: The Rabies Virus Paradigm

   • Karl-Klaus Conzelmann

   Pages 1-20

3. Sendai Virus Biology and Engineering Leading up to the Development of a Novel Class of Expression Vector

   • Yoshiyuki Nagai, Atsushi Kato

   Pages 21-68

4. Concept and Technology Underlying Sendai Virus (SeV) Vector Development

   • Akihiro Iida, Makoto Inoue

   Pages 69-89

5. Genome Replication-Incompetent Sendai Virus Vaccine Vector Against Respiratory Viral Infections That Is Capable of Eliciting a Broad Spectrum of Specific Immune Response

   • Marian Wiegand, Wolfgang J. Neubert

   Pages 91-126

6. Development of Vaccines Using SeV Vectors Against AIDS and Other Infectious Diseases

   • Sayuri Seki, Tetsuro Matano

   Pages 127-149

7. BioKnife, a Modified Sendai Virus, to Resect Malignant Tumors

   • Yoshikazu Yonemitsu, Yasuji Ueda, Mamoru Hasegawa

   Pages 151-169

8. Induction of Human Pluripotent Stem Cells by the Sendai Virus Vector: Establishment of a Highly Efficient and Footprint-Free System

   • Noemi Fusaki, Hiroshi Ban

   Pages 171-183

9. Gene Therapy for Peripheral Arterial Disease Using Sendai Virus Vector: From Preclinical Studies to the Phase I/IIa Clinical Trial

   • Yoshikazu Yonemitsu, Takuya Matsumoto, Yoshihiko Maehara

   Pages 185-199

10. Back Matter

    Pages 201-210

    PDF

Sendai virus (SeV) is not just a mouse pathogen but is evolving into a cutting-edge component of biotechnology. SeV reverse genetics originating from a pure academic need to settle long-held questions in the biology and pathogenicity of nonsegmented negative strand RNA viruses (Mononegavirales) is about to bear the impressive fruit of multipurpose cytoplasmic (non-integrating) RNA vectors. This book brings together in one source the SeV biology revealed by conventional approaches and reverse genetics, the methods to construct the first-generation SeV vector and to generate safer versions, and the applications in medical settings that have left or are about to leave the laboratory bench. The applications, which already are diverse and have high medical impact, include use as vaccine vectors against AIDS and respiratory virus infections, creation of BioKnife to resect malignant tumors, induction of “footprint (transgene) free” pluripotent stem cells, and gene therapy for peripheral arterial disease. These achievements—which are just a few of many examples—were attainable only after rigorously incorporating the rich knowledge of SeV biology that has accumulated during the several decades since the discovery of the virus. Application of SeV vector is certain to expand greatly because of its extremely high performance in transgene expression and its remarkable target cell breadth.

• Gene therapy
• Nonsegmented negative strand RNA virus
• Sendai virus (SeV)
• Transgene
• Vector development
• Viral vectors
• iPS
• transduction
• gene expression

• CRNID, RIKEN, Tokyo, Japan

  Yoshiyuki Nagai

Editor
Yoshiyuki Nagai, M.D. Ph.D.
Director, RIKEN Center of Research Network for Infectious Diseases, Japan

Policies and ethics